Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan: the world's No 2 clinical diagnostics market

This article was originally published in Clinica

Executive Summary

The clinical diagnostics market in Japan has begun to exhibit moderate growth after an extended period of stagnation linked to the dormant Japanese economy. The volume of clinical diagnostic tests performed in Japan declined at single-digit rates in the early 2000s, including decreases in sales of immunodiagnostic tests. Growth in the Japanese clinical diagnostics market is still projected to be slow relative to the overall global market but, based on recent sales figures from Japanese suppliers, has recovered substantially and will approach the rate forecast for the US over the 2010-2015 period. In spite of its slow growth, Japan is the second-largest country market worldwide for clinical diagnostics products after the US, and accounts for over 10% of the global market.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT097672

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel